ReviewRheumatology international2011
Treatment of refractory adult-onset Still's disease with tocilizumab: report of two cases and review of the literature.
Review in Rheumatology international, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.
- Tocilizumab in the treatment of the adult-onset Still's disease: current clinical evidence.Clinical rheumatology · 2013Pooled it
- Adult-onset Still's Disease (AOSD) with Gastrointestinal Lesions.Internal medicine (Tokyo, Japan) · 2024Article
- Adult-onset Still's disease masquerading as acute coronary syndrome: a case report and review of the literature.Journal of medical case reports · 2024Review
- Pyroptosis: the potential eye of the storm in adult-onset Still's disease.Inflammopharmacology · 2023Review
- Cardiac Tamponade During Tocilizumab Therapy in a Patient with Rheumatoid Arthritis and Anti-DNA Antibody Positivity.Internal medicine (Tokyo, Japan) · 2021Article
- Mechanisms, biomarkers and targets for adult-onset Still's disease.Nature reviews. Rheumatology · 2018Review
- Tocilizumab (Actemra).Human vaccines & immunotherapeutics · 2017Review
- Adult-onset Still's disease as a mask of Hodgkin lymphoma.Reumatologia · 2015Article
- [Interleukin-6 inhibition as a potential therapeutic target in rheumatic diseases].Zeitschrift fur Rheumatologie · 2014Review
- [Rare cause of acute liver failure].Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen · 2012Article
- Successful treatment of adult-onset Still's disease with tocilizumab monotherapy: two case reports and literature review.Clinical rheumatology · 2012Review
- Targeting interleukin-6: all the way to treat autoimmune and inflammatory diseases.International journal of biological sciences · 2012Review
- Adult Onset Still's Disease and Autoinflammation.International journal of inflammation · 2012Article
- Adult-Onset Still's Disease: From Pathophysiology to Targeted Therapies.International journal of inflammation · 2012Article
- Tocilizumab for the treatment of rheumatoid arthritis and other systemic autoimmune diseases: current perspectives and future directions.International journal of rheumatology · 2012Article
- Still disease and the liver-an underappreciated association.Gastroenterology & hepatology · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adult-onset Still's disease (AOSD) is empirically treated with nonsteroidal anti-inflammatory drugs, corticosteroids, conventional disease-modifying antirheumatic drugs, tumor necrosis factor-blocking agents or anakinra. The monoclonal anti-interleukin (IL)-6 antibody tocilicumab (TOC) has recently been approved for the treatment of rheumatoid arthritis and may be an attractive therapeutic option for AOSD as well. We report two AOSD patients treated with TOC and review of the current data on the use of TOC in AOSD. TOC was applied to the first patient after failure of cloroquin, methotrexate, adalimumab and etanercept. The second patient received TOC because of inefficacious methotrexate treatment. TOC was well tolerated by both the patients, and no clinically significant side effects occurred. Including these two cases, a total of seven AOSD patients have been successfully treated with TOC so far. TOC may be a promising treatment option for AOSD patients refractory to conventional disease-modifying antirheumatic drugs anakinra and tumor necrosis factor-[Formula: see text].
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.